TY - JOUR
T1 - Advanced Continuous Flow Platform for On-Demand Pharmaceutical Manufacturing
AU - Zhang, Ping
AU - Weeranoppanant, Nopphon
AU - Thomas, Dale A.
AU - Tahara, Kohei
AU - Stelzer, Torsten
AU - Russell, Mary Grace
AU - O'Mahony, Marcus
AU - Myerson, Allan S.
AU - Lin, Hongkun
AU - Kelly, Liam P.
AU - Jensen, Klavs F.
AU - Jamison, Timothy F.
AU - Dai, Chunhui
AU - Cui, Yuqing
AU - Briggs, Naomi
AU - Beingessner, Rachel L.
AU - Adamo, Andrea
N1 - Publisher Copyright:
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2018/2/21
Y1 - 2018/2/21
N2 - As a demonstration of an alternative to the challenges faced with batch pharmaceutical manufacturing including the large production footprint and lengthy time-scale, we previously reported a refrigerator-sized continuous flow system for the on-demand production of essential medicines. Building on this technology, herein we report a second-generation, reconfigurable and 25 % smaller (by volume) continuous flow pharmaceutical manufacturing platform featuring advances in reaction and purification equipment. Consisting of two compact [0.7 (L)×0.5 (D)×1.3 m (H)] stand-alone units for synthesis and purification/formulation processes, the capabilities of this automated system are demonstrated with the synthesis of nicardipine hydrochloride and the production of concentrated liquid doses of ciprofloxacin hydrochloride, neostigmine methylsulfate and rufinamide that meet US Pharmacopeia standards.
AB - As a demonstration of an alternative to the challenges faced with batch pharmaceutical manufacturing including the large production footprint and lengthy time-scale, we previously reported a refrigerator-sized continuous flow system for the on-demand production of essential medicines. Building on this technology, herein we report a second-generation, reconfigurable and 25 % smaller (by volume) continuous flow pharmaceutical manufacturing platform featuring advances in reaction and purification equipment. Consisting of two compact [0.7 (L)×0.5 (D)×1.3 m (H)] stand-alone units for synthesis and purification/formulation processes, the capabilities of this automated system are demonstrated with the synthesis of nicardipine hydrochloride and the production of concentrated liquid doses of ciprofloxacin hydrochloride, neostigmine methylsulfate and rufinamide that meet US Pharmacopeia standards.
KW - active pharmaceutical ingredients
KW - continuous flow chemistry
KW - industrial chemistry
KW - synthetic methods
UR - http://www.scopus.com/inward/record.url?scp=85041183424&partnerID=8YFLogxK
U2 - 10.1002/chem.201706004
DO - 10.1002/chem.201706004
M3 - Article
C2 - 29385292
AN - SCOPUS:85041183424
SN - 0947-6539
VL - 24
SP - 2776
EP - 2784
JO - Chemistry - A European Journal
JF - Chemistry - A European Journal
IS - 11
ER -